John Gordon Freund Sells 500000 Shares of Sutro Biopharma Inc (NASDAQ:STRO) Stock
Sutro Biopharma Inc (NASDAQ:STRO) Director John Gordon Freund sold 500,000 shares of Sutro Biopharma stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $8.72, for a total value of $4,360,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Sutro Biopharma stock traded down $0.08 during mid-day trading on Friday, reaching $8.81. 66,200 shares of the company’s stock traded hands, compared to its average volume of 117,129. Sutro Biopharma Inc has a 12-month low of $6.00 and a 12-month high of $12.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.29 and a quick ratio of 7.29. The stock has a 50 day moving average of $8.40 and a two-hundred day moving average of $9.45.
STRO has been the subject of a number of recent research reports. B. Riley downgraded Sutro Biopharma to a “hold” rating in a research note on Tuesday, May 12th. Wells Fargo & Co began coverage on Sutro Biopharma in a research note on Thursday, July 16th. They issued an “overweight” rating and a $18.00 price objective for the company. HC Wainwright decreased their target price on Sutro Biopharma from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Zacks Investment Research cut Sutro Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, BidaskClub raised shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.79.
Several institutional investors have recently bought and sold shares of STRO. Federated Hermes Inc. bought a new stake in Sutro Biopharma during the 2nd quarter valued at $29,000. American International Group Inc. grew its stake in Sutro Biopharma by 59.3% during the 2nd quarter. American International Group Inc. now owns 10,260 shares of the company’s stock worth $80,000 after buying an additional 3,820 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in Sutro Biopharma during the 4th quarter worth $127,000. UBS Group AG increased its position in Sutro Biopharma by 54.9% during the 4th quarter. UBS Group AG now owns 13,464 shares of the company’s stock valued at $148,000 after buying an additional 4,774 shares in the last quarter. Finally, First Quadrant L P CA purchased a new stake in Sutro Biopharma in the second quarter valued at about $120,000. Hedge funds and other institutional investors own 51.10% of the company’s stock.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Recommended Story: How much can an individual set aside as a catch-up contribution?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 REITS Analysts Can’t Stop Recommending
There are more than 200 publicly-traded real-estate investment trusts (REITs) that you can buy through your brokerage account. Given the sheer number of REITs, it can be hard to identify which real-estate stocks are going to outperform the market.
Fortunately, Wall Street’s brightest minds have already done this for us. Every year, analyst issue approximately 4,000 distinct recommendations for REITs. Analysts don’t always get their “buy” ratings right, but it’s worth taking a hard look when several analysts from different brokerages and research firm are giving “strong buy” and “buy” ratings to the same REIT.
This slide show lists the 15 REITs that have the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.
Published at Sat, 22 Aug 2020 00:45:00 +0000